Asthma management in pregnancy

PLoS One. 2013 Apr 4;8(4):e60247. doi: 10.1371/journal.pone.0060247. Print 2013.

Abstract

Background: Asthma is common during pregnancy, however research is limited regarding the extent and timing of changes in asthma management associated with pregnancy.

Objective: To determine the prevalence of asthma during pregnancy and identify changes in treatment and asthma exacerbation rates associated with pregnancy, while controlling for seasonal influences.

Methods: Pregnant women with asthma were identified from the UK General Practice Research Database between 2000 and 2008. For each woman asthma medication prescribed during the study period was identified; for each product combination the British Thoracic Society medication-defined asthma treatment step was identified. Asthma exacerbations were identified during pregnancy and in the corresponding 12 months prior. Analyses of changes in asthma treatment and exacerbation rates during pregnancy relative to the corresponding period 12 months prior, to control for seasonality, were stratified by trimester and asthma treatment intensity level.

Results: The prevalence of treated asthma in pregnancies resulting in a delivery was 8.3%. From 14,141 pregnancies, in 12,828 women with asthma, 68.4% received prescriptions for a short-acting β2-agonist and 41.2% for inhaled corticosteroids; 76.5% were managed with asthma treatment Step 1 or 2. Poor persistence to inhaled corticosteroids, defined as a gap of up to 60 days between prescriptions, was common. In 45.0% of pregnancies, an increase in average treatment step was observed whereas in 25.6% the treatment step decreased. Treatment intensity remained the same in 29.5% of pregnancies. Exacerbations occurred in 4.8% of pregnancies compared to 5.9% in the same season the year before (p<0.001).

Conclusion: Exacerbation rates during pregnancy were slightly lower than in the year before. However, treatment patterns and exacerbation rates in this study suggest asthma control during pregnancy is variable, and women may require close monitoring especially in those with evidence of poor control before pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / drug therapy*
  • Asthma / epidemiology*
  • Databases, Factual
  • Female
  • Humans
  • Middle Aged
  • Population Surveillance
  • Pregnancy
  • Pregnancy Complications*
  • Pregnancy Outcome
  • Pregnancy Trimesters
  • Prevalence
  • Risk Factors
  • Young Adult

Substances

  • Anti-Asthmatic Agents

Grant support

This study was funded by GlaxoSmithKline; protocol number WEUKBRE5848. The authors affiliated with GlaxoSmithKline were involved in the study design and preparation of the manuscript but played no role in data collection and analysis. An unequivocal contractual agreement was in place to ensure that the University of Bath had complete freedom to publish.